A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials (Q57570787)

Jean-Yves Blay

3

0 references

Axel Le Cesne

1

Axel Le Cesne

0 references

Suzette Delaloge

4

Suzette Delaloge

0 references

George D Demetri

10

George D. Demetri

0 references

author name string

Alejandro Yovine

2

0 references

Jean-Louis Misset

6

0 references

Pilar Frontelo

7

0 references

Antonio Nieto

8

0 references

Juhui James Jiao

Investigational New Drugs

9

0 references

publication date

12 April 2011

0 references

published in

0 references

volume

30

0 references

issue

3

0 references

page(s)

1193-1202

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10637-011-9662-0

0 references

cites work

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

7512 POSTER Assessing the clinical impact of trabectedin in patients with leiomyosarcomas or liposarcomas (L-sarcomas) progressing despite prior conventional chemotherapy: clinical benefit rate, growth modulation index and tumor variation as paramete

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Epirubicin and ifosfamide in advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

The use of chemotherapy in soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Hepatotoxicity and metabolism of trabectedin: a literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9662-0

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

12 December 2020

Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study

1 reference

12 December 2020

Ecteinascidin-743 inhibits activated but not constitutive transcription.

1 reference

12 December 2020

Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study

1 reference

12 December 2020